FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2556647624> ?p ?o ?g. }

• W2556647624 abstract "ABSTRACT Although human immunodeficiency virus (HIV) coinfection is the most important risk factor for a poor antituberculosis (anti-TB) treatment response, its effect on the pharmacokinetics of the first-line drugs in children is understudied. This study examined the pharmacokinetics of the four first-line anti-TB drugs in children with TB with and without HIV coinfection. Ghanaian children with TB on isoniazid, rifampin, pyrazinamide, and ethambutol for at least 4 weeks had blood samples collected predose and at 1, 2, 4, and 8 hours postdose. Drug concentrations were determined by validated liquid chromatography-mass spectrometry methods and pharmacokinetic parameters calculated using noncompartmental analysis. The area under the concentration-time curve from 0 to 8 h (AUC 0–8 ), maximum concentration ( C max ), and apparent oral clearance divided by bioavailability (CL/F) for each drug were compared between children with and without HIV coinfection. Of 113 participants, 59 (52.2%) had HIV coinfection. The baseline characteristics were similar except that the coinfected patients were more likely to have lower weight-for-age and height-for-age Z scores ( P < 0.05). Rifampin, pyrazinamide, and ethambutol median body weight-normalized CL/F values were significantly higher, whereas the plasma AUC 0–8 values were lower, in the coinfected children than in those with TB alone. In the multivariate analysis, drug dose and HIV coinfection jointly influenced the apparent oral clearance and AUC 0–8 for rifampin, pyrazinamide, and ethambutol. Isoniazid pharmacokinetics were not different by HIV coinfection status. HIV coinfection was associated with lower plasma exposure of three of the four first-line anti-TB drugs in children. Whether TB/HIV-coinfected children need higher dosages of rifampin, pyrazinamide, and ethambutol requires further investigation. (This study has been registered at ClinicalTrials.gov under identifier NCT01687504.)" @default.
• W2556647624 created "2016-11-30" @default.
• W2556647624 creator A5023039183 @default.
• W2556647624 creator A5024906207 @default.
• W2556647624 creator A5032085827 @default.
• W2556647624 creator A5032686679 @default.
• W2556647624 creator A5035478609 @default.
• W2556647624 creator A5037684823 @default.
• W2556647624 creator A5044162218 @default.
• W2556647624 creator A5053945845 @default.
• W2556647624 creator A5055231042 @default.
• W2556647624 creator A5059101690 @default.
• W2556647624 creator A5072988639 @default.
• W2556647624 creator A5073239264 @default.
• W2556647624 creator A5073438039 @default.
• W2556647624 creator A5074369102 @default.
• W2556647624 date "2017-02-01" @default.
• W2556647624 modified "2023-09-28" @default.
• W2556647624 title "Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection" @default.
• W2556647624 cites W1922118029 @default.
• W2556647624 cites W1965125844 @default.
• W2556647624 cites W1967990665 @default.
• W2556647624 cites W1981884897 @default.
• W2556647624 cites W1984199840 @default.
• W2556647624 cites W2009816311 @default.
• W2556647624 cites W2015111344 @default.
• W2556647624 cites W2021045213 @default.
• W2556647624 cites W2044627778 @default.
• W2556647624 cites W2051831532 @default.
• W2556647624 cites W2061399828 @default.
• W2556647624 cites W2063831126 @default.
• W2556647624 cites W2075098875 @default.
• W2556647624 cites W2076191577 @default.
• W2556647624 cites W2097210644 @default.
• W2556647624 cites W2098698934 @default.
• W2556647624 cites W2116370212 @default.
• W2556647624 cites W2116664557 @default.
• W2556647624 cites W2118976331 @default.
• W2556647624 cites W2120343562 @default.
• W2556647624 cites W2121763061 @default.
• W2556647624 cites W2122682841 @default.
• W2556647624 cites W2124135615 @default.
• W2556647624 cites W2131368119 @default.
• W2556647624 cites W2134099620 @default.
• W2556647624 cites W2134538141 @default.
• W2556647624 cites W2147213334 @default.
• W2556647624 cites W2147574313 @default.
• W2556647624 cites W2169521076 @default.
• W2556647624 cites W2170452898 @default.
• W2556647624 cites W2322937695 @default.
• W2556647624 cites W2324439816 @default.
• W2556647624 cites W2336896130 @default.
• W2556647624 cites W2341767046 @default.
• W2556647624 cites W2411171235 @default.
• W2556647624 cites W2463232350 @default.
• W2556647624 cites W3106108064 @default.
• W2556647624 cites W88228589 @default.
• W2556647624 doi "https://doi.org/10.1128/aac.01701-16" @default.
• W2556647624 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5278726" @default.
• W2556647624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27855070" @default.
• W2556647624 hasPublicationYear "2017" @default.
• W2556647624 type Work @default.
• W2556647624 sameAs 2556647624 @default.
• W2556647624 citedByCount "26" @default.
• W2556647624 countsByYear W25566476242017 @default.
• W2556647624 countsByYear W25566476242018 @default.
• W2556647624 countsByYear W25566476242019 @default.
• W2556647624 countsByYear W25566476242020 @default.
• W2556647624 countsByYear W25566476242021 @default.
• W2556647624 countsByYear W25566476242022 @default.
• W2556647624 countsByYear W25566476242023 @default.
• W2556647624 crossrefType "journal-article" @default.
• W2556647624 hasAuthorship W2556647624A5023039183 @default.
• W2556647624 hasAuthorship W2556647624A5024906207 @default.
• W2556647624 hasAuthorship W2556647624A5032085827 @default.
• W2556647624 hasAuthorship W2556647624A5032686679 @default.
• W2556647624 hasAuthorship W2556647624A5035478609 @default.
• W2556647624 hasAuthorship W2556647624A5037684823 @default.
• W2556647624 hasAuthorship W2556647624A5044162218 @default.
• W2556647624 hasAuthorship W2556647624A5053945845 @default.
• W2556647624 hasAuthorship W2556647624A5055231042 @default.
• W2556647624 hasAuthorship W2556647624A5059101690 @default.
• W2556647624 hasAuthorship W2556647624A5072988639 @default.
• W2556647624 hasAuthorship W2556647624A5073239264 @default.
• W2556647624 hasAuthorship W2556647624A5073438039 @default.
• W2556647624 hasAuthorship W2556647624A5074369102 @default.
• W2556647624 hasBestOaLocation W25566476241 @default.
• W2556647624 hasConcept C112705442 @default.
• W2556647624 hasConcept C126322002 @default.
• W2556647624 hasConcept C142724271 @default.
• W2556647624 hasConcept C203014093 @default.
• W2556647624 hasConcept C2776228421 @default.
• W2556647624 hasConcept C2776967927 @default.
• W2556647624 hasConcept C2777813720 @default.
• W2556647624 hasConcept C2780459521 @default.
• W2556647624 hasConcept C2781069245 @default.
• W2556647624 hasConcept C3013748606 @default.
• W2556647624 hasConcept C71924100 @default.
• W2556647624 hasConcept C90924648 @default.
• W2556647624 hasConcept C98274493 @default.

• next